Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

References

• FriedmanDSWolfsRCO’ColmainBJPrevalence of open-angle glaucoma among adults in the United StatesArch Ophthalmol2004122453253815078671
   PubMedGoogle Scholar
• ThyleforsBNégrelADThe global impact of glaucomaBull World Health Organ19947233233268062393
   PubMed Web of Science ®Google Scholar
• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• AgarwalRGuptaSKAgarwalPSaxenaRAgrawalSSCurrent concepts in the pathophysiology of glaucomaIndian J Ophthalmol200957425726619574692
   PubMed Web of Science ®Google Scholar
• PillunatLEStodtmeisterRMarquardtRMatternAOcular perfusion pressures in different types of glaucomaInt Ophthalmol1989131–237422744953
   PubMed Web of Science ®Google Scholar
• QuarantaLManniGDonatoFBucciMGThe effect of increased intraocular pressure on pulsatile ocular blood flow in low tension glaucomaSurv Ophthalmol199438SupplS177S181 discussion S1827940140
   PubMedGoogle Scholar
• QuarantaLKatsanosARussoARivaI24-hour intraocular pressure and ocular perfusion pressure in glaucomaSurv Ophthalmol2013581264123217586
   PubMed Web of Science ®Google Scholar
• GrunwaldJESinclairSHRivaCEAutoregulation of the retinal circulation in response to decrease of intraocular pressure below normalInvest Ophthalmol Vis Sci19822311241277085215
   PubMed Web of Science ®Google Scholar
• PillunatLEAndersonDRKnightonRWJoosKMFeuerWJAutoregulation of human optic nerve head circulation in response to increased intraocular pressureExp Eye Res19976457377449245904
   PubMed Web of Science ®Google Scholar
• OjhaPWiggsJLPasqualeLRThe genetics of intraocular pressureSemin Ophthalmol2013285–630130524138038
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHymanLBengtssonBKomaroffEFactors for progression and glaucoma treatment: the Early Manifest Glaucoma TrialCurr Opin Ophthalmol200415210210615021220
   PubMedGoogle Scholar
• Garway-HeathDFCrabbDPBunceCLatanoprost for open- angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trialLancet Epub20141218
   Google Scholar
• RulliEBiagioliERivaIEfficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysisJAMA Ophthalmol2013131121573158224158640
   PubMed Web of Science ®Google Scholar
• SharifNAKellyCRCriderJYAgonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptorJ Ocul Pharmacol Ther200218431332412222762
   PubMed Web of Science ®Google Scholar
• SharifNAKellyCRCriderJYHuman trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analoguesInvest Ophthalmol Vis Sci200344271572112556403
   PubMed Web of Science ®Google Scholar
• BeanGWCamrasCBCommercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differencesSurv Ophthalmol200853Suppl 1S69S8419038626
   PubMed Web of Science ®Google Scholar
• BitoLZBaroodyRAThe ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl esterExp Eye Res19874422172263472899
   PubMed Web of Science ®Google Scholar
• VillumsenJAlmASöderströmMProstaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucomaBr J Ophthalmol198973129759792611194
   PubMed Web of Science ®Google Scholar
• HellbergMRSalleeVLMcLaughlinMAPreclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonistJ Ocul Pharmacol Ther200117542143211765147
   PubMed Web of Science ®Google Scholar
• DenisPCovertDRealiniATravoprost in the management of open-angle glaucoma and ocular hypertensionClin Ophthalmol200711112419668462
   PubMedGoogle Scholar
• McCueBACasonMMCurtisMAFaulknerRDDahlinDCDetermination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MSJ Pharm Biomed Anal200228219920811929662
   PubMed Web of Science ®Google Scholar
• TorisCBGabeltBTKaufmanPLUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reductionSurv Ophthalmol200853Suppl 1S107S12019038618
   PubMed Web of Science ®Google Scholar
• TorisCBZhanGLCamrasCBMcLaughlinMAEffects of travoprost on aqueous humor dynamics in monkeysJ Glaucoma2005141707315650608
   PubMed Web of Science ®Google Scholar
• TorisCBZhanGFanSEffects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressureJ Glaucoma200716218919517473728
   PubMed Web of Science ®Google Scholar
• Schlötzer-SchrehardtUZenkelMNüsingRMExpression and localization of FP and EP prostanoid receptor subtypes in human ocular tissuesInvest Ophthalmol Vis Sci20024351475148711980863
   PubMed Web of Science ®Google Scholar
• OcklindAEffect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sectionsExp Eye Res19986721791919733584
   PubMed Web of Science ®Google Scholar
• SagaraTGatonDDLindseyJDGabeltBTKaufmanPLWeinrebRNTopical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathwayArch Ophthalmol1999117679480110369592
   PubMedGoogle Scholar
• PoyerJFMillarCKaufmanPLProstaglandin F2 alpha effects on isolated rhesus monkey ciliary muscleInvest Ophthalmol Vis Sci19953612246124657591635
   PubMed Web of Science ®Google Scholar
• AlphenGWWilhelmPBElsenfeldPWThe effect of prostaglandins on the isolated internal muscles of the mammalian eye, including manDoc Ophthalmol1977422397415405187
   PubMed Web of Science ®Google Scholar
• StjernschantzJSelénGOcklindAResulBEffects of latanoprost and related prostaglandin analoguesAlmWeinrebRNUveoscleral Outflow. Biology and Clinical AspectsLondon, UKMosby International Limited19985772
   Google Scholar
• GatonDDSagaraTLindseyJDGabeltBTKaufmanPLWeinrebRNIncreased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatmentArch Ophthalmol200111981165117011483084
   PubMed Web of Science ®Google Scholar
• HusainSJafriFCrossonCEAcute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent processInvest Ophthalmol Vis Sci20054651706171315851572
   PubMed Web of Science ®Google Scholar
• Lutjen-DrecollETammEMorphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alphaExp Eye Res19884757617693197775
   PubMed Web of Science ®Google Scholar
• NilssonSFDrecollELütjen-DrecollEThe prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkeyInvest Ophthalmol Vis Sci20064794042404916936121
   PubMed Web of Science ®Google Scholar
• RichterMKraussAHWoodwardDFLutjen-DrecollEMorphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamideInvest Ophthalmol Vis Sci200344104419442614507888
   PubMed Web of Science ®Google Scholar
• KrebsWKrebsIPUltrastructural evidence for lymphatic capillaries in the primate choroidArch Ophthalmol198810611161516163190548
   PubMedGoogle Scholar
• AlexanderJPSamplesJRVan BuskirkEMAcottTSExpression of matrix metalloproteinases and inhibitor by human trabecular meshworkInvest Ophthalmol Vis Sci19913211721801846130
   PubMed Web of Science ®Google Scholar
• BradleyJMVrankaJColvisCMEffect of matrix metalloproteinases activity on outflow in perfused human organ cultureInvest Ophthalmol Vis Sci19983913264926589856774
   PubMed Web of Science ®Google Scholar
• VaajanenAVapaataloHOksalaOA modified in vitro method for aqueous humor outflow studies in enucleated porcine eyesJ Ocul Pharmacol Ther200723212413117444800
   PubMed Web of Science ®Google Scholar
• BahlerCKHowellKGHannCRFautschMPJohnsonDHProstaglandins increase trabecular meshwork outflow facility in cultured human anterior segmentsAm J Ophthalmol2008145111411917988642
   PubMed Web of Science ®Google Scholar
• ZhaoXPearsonKEStephanDARussellPEffects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cellsInvest Ophthalmol Vis Sci20034451945195212714628
   PubMed Web of Science ®Google Scholar
• EisenbergDLTorisCBCamrasCBBimatoprost and travoprost: a review of recent studies of two new glaucoma drugsSurv Ophthalmol200247Suppl 1S105S11512204706
   PubMed Web of Science ®Google Scholar
• HolmstromSBuchholzPWaltJWickstrømJAagrenMAnalytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucomaCurr Med Res Opin200521111875188316307709
   PubMed Web of Science ®Google Scholar
• van der ValkRWebersCASchoutenJSZeegersMPHendrikseFPrinsMHIntraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trialsOphthalmology200511271177118515921747
   PubMed Web of Science ®Google Scholar
• KonstasAGMikropoulosDKaltsosKJenkinsJNStewartWC24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucomaOphthalmology2006113344645016513458
   PubMed Web of Science ®Google Scholar
• KonstasAGMikropoulosDHaidichABNtamposKSStewartWCTwenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucomaBr J Ophthalmol200993448148519019932
   PubMed Web of Science ®Google Scholar
• StewartWCKonstasAGNelsonLAKruftBMeta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicinesOphthalmology2008115711171122.e118082886
   PubMed Web of Science ®Google Scholar
• DubinerHBSircyMDLandryTComparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressureClin Ther2004261849114996520
   PubMed Web of Science ®Google Scholar
• RivaIKatsanosAFlorianiILong-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucomaJ Glaucoma201423853554024786103
   PubMed Web of Science ®Google Scholar
• GoldbergICunha-VazJJakobsenJEComparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertensionJ Glaucoma200110541442211711841
   PubMed Web of Science ®Google Scholar
• FellmanRLSullivanEKRatliffMComparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trialOphthalmology20021095998100811986110
   PubMed Web of Science ®Google Scholar
• NetlandPALandryTSullivanEKTravoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertensionAm J Ophthalmol2001132447248411589866
   PubMed Web of Science ®Google Scholar
• BarnebeyHSOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol200514011715990081
   PubMed Web of Science ®Google Scholar
• LiNChenXMZhouYWeiMLYaoXTravoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trialsClin Experiment Ophthalmol200634875576417073898
   PubMed Web of Science ®Google Scholar
• HollóGThelenUTeusMALong-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in EuropeJ Ocul Pharmacol Ther201127549349821790326
   PubMed Web of Science ®Google Scholar
• ParrishRKPalmbergPSheuWPXLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• NoeckerRJEarlMLMundorfTPeaceJWilliamsRDBimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertensionAdv Ther200320212112812836812
   PubMed Web of Science ®Google Scholar
• CardasciaNVetrugnoMTrabuccoTCantatoreFSborgiaCEffects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucomaCurr Ther Res Clin Exp200364738940024944390
   PubMed Web of Science ®Google Scholar
• KonstasAGKozobolisVPKatsimprisIEEfficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patientsOphthalmology2007114465365717197028
   PubMed Web of Science ®Google Scholar
• CantorLBHoopJMorganLWudunnDCatoiraYBimatoprost-Travoprost Study GroupIntraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertensionBr J Ophthalmol200690111370137316825272
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol20021206701713 discussion 829–83012049574
   PubMed Web of Science ®Google Scholar
• HughesBABacharachJCravenERA three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertensionJ Glaucoma200514539239916148589
   PubMed Web of Science ®Google Scholar
• SchumanJSKatzGJLewisRAEfficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertensionAm J Ophthalmol2005140224225016086946
   PubMed Web of Science ®Google Scholar
• QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther201329438238923231442
   PubMed Web of Science ®Google Scholar
• NoeckerREffects of common ophthalmic preservatives on ocular healthAdv Ther200118520521511783457
   PubMed Web of Science ®Google Scholar
• BaudouinCLiangHHamardPThe ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathwaysOphthalmology2008115110911517532048
   PubMed Web of Science ®Google Scholar
• BroadwayDCGriersonIO’BrienCHitchingsRAAdverse effects of topical antiglaucoma medication. I. The conjunctival cell profileArch Ophthalmol199411211143714457980133
   PubMedGoogle Scholar
• BursteinNLCorneal cytotoxicity of topically applied drugs, vehicles and preservativesSurv Ophthalmol198025115306998034
   PubMed Web of Science ®Google Scholar
• IshibashiTYokoiNKinoshitaSComparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chlorideJ Glaucoma200312648649014646684
   PubMed Web of Science ®Google Scholar
• BoimerCBirtCMPreservative exposure and surgical outcomes in glaucoma patients: The PESO studyJ Glaucoma201322973073523524856
   PubMed Web of Science ®Google Scholar
• Brignole-BaudouinFRianchoLLiangHBaudouinCComparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cellsCurr Eye Res2011361197998821999224
   PubMed Web of Science ®Google Scholar
• LiangHBrignole-BaudouinFRianchoLBaudouinCReduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutionsOphthalmic Res20124828910122473057
   PubMed Web of Science ®Google Scholar
• ChoyCKChoPBoostMVCytotoxicity and effects on metabolism of contact lens care solutions on human corneal epithelium cellsClin Exp Optom201295219820622233282
   PubMed Web of Science ®Google Scholar
• ChoyCKChoPBoostMVBenzieIFDo multipurpose solutions damage porcine corneal epithelial cells?Optom Vis Sci2009865E447E45319319011
   PubMed Web of Science ®Google Scholar
• LewisRAKatzGJWeissMJTravoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma20071619810317224758
   PubMed Web of Science ®Google Scholar
• HenryJCPeaceJHStewartJAStewartWCEfficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapyClin Ophthalmol20082361362119668762
   PubMedGoogle Scholar
• FukuchiTWakaiKSudaKIncidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medicationsClin Ophthalmol2010420320920463785
   PubMedGoogle Scholar
• Alcon ResearchTravoprost 3-Month Safety and Efficacy Study Available from: https://clinicaltrials.gov/show/NCT01453855. NLM Identifier: NCT01453855Accessed January 17, 2014
   Google Scholar
• Alcon ResearchStudy of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Available from: https://clinicaltrials.gov/show/NCT01652664. NLM Identifier: NCT01652664Accessed January 17, 2014
   Google Scholar
• YanovitchTLEnyediLBSchotthoefferEOFreedmanSFTravoprost in children: adverse effects and intraocular pressure responseJ AAPOS2009131919319233013
   PubMed Web of Science ®Google Scholar
• AlmAGriersonIShieldsMBSide effects associated with prostaglandin analog therapySurv Ophthalmol200853Suppl 1S93S10519038628
   PubMed Web of Science ®Google Scholar
• AstinMStjernschantzJSelénGRole of nitric oxide in PGF2 alpha-induced ocular hyperemiaExp Eye Res19945944014077532135
   PubMed Web of Science ®Google Scholar
• AstinMStjernschantzJMediation of prostaglandin f2 alpha-induced ocular surface hyperemia by sensory nerves in rabbitsCurr Eye Res19971698868909288449
   PubMed Web of Science ®Google Scholar
• AstinMStjernschantzJMechanism of prostaglandin E2-, F2alpha- and latanoprost acid-induced relaxation of submental veinsEur J Pharmacol19973402–31952019537815
   PubMed Web of Science ®Google Scholar
• TostiAPazzagliaMVoudourisSTostiGHypertrichosis of the eyelashes caused by bimatoprostJ Am Acad Dermatol2004515 SupplS149S15015577756
   PubMed Web of Science ®Google Scholar
• ColombeLMicheletJFBernardBAProstanoid receptors in anagen human hair folliclesExp Dermatol2008171637218005048
   PubMed Web of Science ®Google Scholar
• BeardenWAndersonRTrichiasis associated with prostaglandin analog useOphthal Plast Reconstr Surg2004204320322
   Web of Science ®Google Scholar
• HartJShafranovGHypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprostAm J Ophthalmol2004137475675715059720
   PubMed Web of Science ®Google Scholar
• O’TooleLCahillMO’BrienCEyelid hypertrichosis associated with latanoprost is reversibleEur J Ophthalmol200111437737911820311
   PubMed Web of Science ®Google Scholar
• WistrandPJStjernschantzJOlssonKThe incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye colorSurv Ophthalmol199741Suppl 2S129S1389154289
   PubMed Web of Science ®Google Scholar
• AlmASchoenfelderJMcDermottJA 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucomaArch Ophthalmol2004122795796515249358
   PubMedGoogle Scholar
• ImeschPDBindleyCDKhademianZMelanocytes and iris color. Electron microscopic findingsArch Ophthalmol199611444434478602783
   PubMedGoogle Scholar
• ProtaGVincensiMRNapolitanoASelenGStjernschantzJLatanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeysPigment Cell Res200013314715010885672
   PubMedGoogle Scholar
• LindquistNGLarssonBSStjernschantzJIncreased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogueExp Eye Res199969443143610504276
   PubMed Web of Science ®Google Scholar
• Smith-ThomasLMoustafaMSpadaCSLatanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependentExp Eye Res200478597398515051478
   PubMed Web of Science ®Google Scholar
• Del Hierro ZarzueloAMartínez de la CasaJMGarcía FeijoóJCastillo GómezAMéndez HernándezCGarcía SánchezJCystoid macular edema induced by travoprostArch Soc Esp Oftalmol2004796295297 Spanish15221676
   PubMedGoogle Scholar
• ArcieriESSantanaARochaFNGuapoGLCostaVPBlood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trialArch Ophthalmol2005123218619215710814
   PubMedGoogle Scholar
• EsquenaziSCystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprostJ Ocul Pharmacol Ther200723656757018001244
   PubMed Web of Science ®Google Scholar
• FaulknerWJBurkSEAcute anterior uveitis and corneal edema associated with travoprostArch Ophthalmol200312171054105512860818
   PubMedGoogle Scholar
• KumarasamyMDesaiSPAnterior uveitis is associated with travoprostBMJ2004329745920515271831
   PubMed Web of Science ®Google Scholar
• SuominenSVälimäkiJBilateral anterior uveitis associated with travoprostActa Ophthalmol Scand200684227527616637856
   PubMedGoogle Scholar
• AydinSOzcuraFCorneal oedema and acute anterior uveitis after two doses of travoprostActa Ophthalmol Scand200785669369417403018
   PubMedGoogle Scholar
• ChiamPTravoprost induced granulomatous anterior uveitisCase Rep Ophthalmol Med2011201150707322606464
   PubMedGoogle Scholar
• CelliniMCaramazzaRBonsantoDBernabiniBCamposECProstaglandin analogs and blood-aqueous barrier integrity: a flare cell meter studyOphthalmologica2004218531231715334011
   PubMed Web of Science ®Google Scholar